Molecular monitoring of the tumor load predicts progressive disease in patients with multiple myeloma after high-dose therapy with autologous peripheral blood stem cell transplantation

Bone Marrow Transplantation

Volumn 28, Issue 10, 2001, Pages 957-962

  Lipinski, E ^a   Cremer, F W ^a   Ho, A D ^a   Goldschmidt, H ^a   Moos, M ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

ASO PCR; Kinetics of tumor load; Myeloma; Prediction of progressive disease; Quantitative PCR

Indexed keywords

ADULT; ALLELE; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLOOD SAMPLING; BONE MARROW; CANCER RECURRENCE; CANCER REGRESSION; CLINICAL ARTICLE; CONTROLLED STUDY; DILUTION; DISEASE COURSE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; MALE; METHODOLOGY; MINIMAL RESIDUAL DISEASE; MONITORING; MULTIPLE MYELOMA; OLIGONUCLEOTIDE PROBE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TIME; TUMOR CELL;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLONE CELLS; DISEASE PROGRESSION; DNA PRIMERS; DNA, NEOPLASM; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM, RESIDUAL; OLIGONUCLEOTIDES; PARAPROTEINS; POLYMERASE CHAIN REACTION; PROGNOSIS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TRANSPLANTATION, AUTOLOGOUS;

EID: 0035194777     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703276     Document Type: Article

References (18)

1. A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma
2. Molecular and clinical remissions in multiple myeloma: Role of autologous and allogeneic transplantation of haematopoietic cells
3. Molecular remission after allogeneic or autologous transplantation of haematopoietic stem cells for multiple myeloma
4. Evaluation of the kinetics of bone marrow tumor load in the course of sequential high-dose therapy assessed by quantitative PCR as predictive factor in patients with multiple myeloma
5. Tandem autologous transplantation (tpx) for multiple myeloma (MM): Results of a German multicenter study
6. High-dose therapy with peripheral blood progenitor cell transplantation in multiple myeloma
7. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haematopoietic stem cell transplantation
8. Quantitative comparison of multiple myeloma tumor contamination in bone marrow harvest and leukapheresis autografts
9. A quantitative PCR assay for the detection of low amounts of malignant cells in multiple myeloma
10. Analysis of circulating tumor cells in patients with multiple myeloma during the course of high-dose therapy with peripheral blood stem cell transplantation
11. Sequential analysis of bone marrow and peripheral blood after stem cell transplant for myeloma shows disparate tumor involvement
12. Frequency and kinetics of polyclonal and clonal B cells in the peripheral blood of patients being treated for multiple myeloma
13. Controversies surrounding the circulating clonotypic B lymphocytes in multiple myeloma
14. Clonotypic B cells in the peripheral blood of patients with multiple myeloma
15. Improved quantitation of minimal residual disease in multiple myeloma using real time PCR and plasmid-DNA complementarity determining region III standards
16. Quantitation of minimal residual disease in multiple myeloma using an allele-specific real-time PCR assay
17. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: A BFM group report
18. A clinical staging system for multiple myeloma: Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival